Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (391-400 of 426) with videos related to

Pageof 43
Sort By:
Nature Communications|May 28, 2025
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stressAndreas Varkaris, Keshan Wang, Mannan Nouri, et al.
Cancer Discovery|April 29, 2017
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Joaquin Mateo, Wei Yuan, et al.
European Urology|September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate CancerChristina Guo, Ines Figueiredo, Bora Gurel, et al.
The New England Journal of Medicine|May 27, 2011
Abiraterone and increased survival in metastatic prostate cancerJohann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
European Urology|May 1, 2019
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate CancerAdam Sharp, Jon C Welti, Maryou B K Lambros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2025
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumorsJohann S de Bono, Anja Williams, Ignacio Melero, et al.
International Journal of Cancer|November 1, 2021
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation studySophie Cousin, Jean-Yves Blay, Irene Braña Garcia, et al.
Cancer Research|April 6, 2021
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate CancerAlec Paschalis, Jonathan Welti, Antje J Neeb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2018
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by ApheresisMaryou B Lambros, George Seed, Semini Sumanasuriya, et al.
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Pageof 43

Showing results (391-400 of 426) with videos related to

Sort By:
Pageof 43
Nature Communications|May 28, 2025
BH3 mimetics targeting BCL-XL have efficacy in solid tumors with RB1 loss and replication stressAndreas Varkaris, Keshan Wang, Mannan Nouri, et al.
Cancer Discovery|April 29, 2017
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP InhibitionJane Goodall, Joaquin Mateo, Wei Yuan, et al.
European Urology|September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate CancerChristina Guo, Ines Figueiredo, Bora Gurel, et al.
The New England Journal of Medicine|May 27, 2011
Abiraterone and increased survival in metastatic prostate cancerJohann S de Bono, Christopher J Logothetis, Arturo Molina, et al.
European Urology|May 1, 2019
Clinical Utility of Circulating Tumour Cell Androgen Receptor Splice Variant-7 Status in Metastatic Castration-resistant Prostate CancerAdam Sharp, Jon C Welti, Maryou B K Lambros, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2025
A phase I dose escalation and cohort expansion study of CB307, a trispecific Humabody® against PSMA, CD137, and albumin in patients with PSMA-positive solid tumorsJohann S de Bono, Anja Williams, Ignacio Melero, et al.
International Journal of Cancer|November 1, 2021
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation studySophie Cousin, Jean-Yves Blay, Irene Braña Garcia, et al.
Cancer Research|April 6, 2021
JMJD6 Is a Druggable Oxygenase That Regulates AR-V7 Expression in Prostate CancerAlec Paschalis, Jonathan Welti, Antje J Neeb, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2018
Single-Cell Analyses of Prostate Cancer Liquid Biopsies Acquired by ApheresisMaryou B Lambros, George Seed, Semini Sumanasuriya, et al.
European Urology|March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Pageof 43